BBI Solutions, Cardiff, United Kingdom, has announced the launch of its recombinant NGAL protein, a new marker for the early diagnosis of acute kidney injury (AKI). Levels of NGAL can be seen to rise in the blood and urine, within 2 hours or less, during acute renal failure. NGAL is secreted in two different forms, a dimer and a monomer. Clinical studies have shown that the monomer is primarily the dominant form of NGAL. The company’s protein has low dimer content in relation to the monomer, and has been designed to provide a purity of >96%, minimizing the risk of interferences due to contaminants. For more information, visit BBI Solutions.